These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 25658463

  • 1. WIP1 phosphatase as a potential therapeutic target in neuroblastoma.
    Richter M, Dayaram T, Gilmartin AG, Ganji G, Pemmasani SK, Van Der Key H, Shohet JM, Donehower LA, Kumar R.
    PLoS One; 2015; 10(2):e0115635. PubMed ID: 25658463
    [Abstract] [Full Text] [Related]

  • 2. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
    Esfandiari A, Hawthorne TA, Nakjang S, Lunec J.
    Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.
    Pechackova S, Burdova K, Benada J, Kleiblova P, Jenikova G, Macurek L.
    Oncotarget; 2016 Mar 22; 7(12):14458-75. PubMed ID: 26883108
    [Abstract] [Full Text] [Related]

  • 5. The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma.
    Kojima K, Maeda A, Yoshimura M, Nishida Y, Kimura S.
    Oncotarget; 2016 Oct 25; 7(43):69625-69637. PubMed ID: 27626308
    [Abstract] [Full Text] [Related]

  • 6. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
    Wu CE, Esfandiari A, Ho YH, Wang N, Mahdi AK, Aptullahoglu E, Lovat P, Lunec J.
    Br J Cancer; 2018 Feb 20; 118(4):495-508. PubMed ID: 29235570
    [Abstract] [Full Text] [Related]

  • 7. Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D.
    Castellino RC, De Bortoli M, Lu X, Moon SH, Nguyen TA, Shepard MA, Rao PH, Donehower LA, Kim JY.
    J Neurooncol; 2008 Feb 20; 86(3):245-56. PubMed ID: 17932621
    [Abstract] [Full Text] [Related]

  • 8. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase.
    Yoda A, Toyoshima K, Watanabe Y, Onishi N, Hazaka Y, Tsukuda Y, Tsukada J, Kondo T, Tanaka Y, Minami Y.
    J Biol Chem; 2008 Jul 04; 283(27):18969-79. PubMed ID: 18482988
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
    Sriraman A, Radovanovic M, Wienken M, Najafova Z, Li Y, Dobbelstein M.
    Oncotarget; 2016 May 31; 7(22):31623-38. PubMed ID: 27183917
    [Abstract] [Full Text] [Related]

  • 11. p53-Independent expression of wild-type p53-induced phosphatase 1 (Wip1) in methylmethane sulfonate-treated cancer cell lines and human tumors.
    Park JY, Song JY, Kim HM, Han HS, Seol HS, Jang SJ, Choi J.
    Int J Biochem Cell Biol; 2012 Jun 31; 44(6):896-904. PubMed ID: 22405851
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. DNA damage-induced regulatory interplay between DAXX, p53, ATM kinase and Wip1 phosphatase.
    Brazina J, Svadlenka J, Macurek L, Andera L, Hodny Z, Bartek J, Hanzlikova H.
    Cell Cycle; 2015 Jun 31; 14(3):375-87. PubMed ID: 25659035
    [Abstract] [Full Text] [Related]

  • 15. The estrogen receptor alpha pathway induces oncogenic Wip1 phosphatase gene expression.
    Han HS, Yu E, Song JY, Park JY, Jang SJ, Choi J.
    Mol Cancer Res; 2009 May 31; 7(5):713-23. PubMed ID: 19435816
    [Abstract] [Full Text] [Related]

  • 16. Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma.
    Fuku T, Semba S, Yutori H, Yokozaki H.
    Pathol Int; 2007 Sep 31; 57(9):566-71. PubMed ID: 17685927
    [Abstract] [Full Text] [Related]

  • 17. Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase.
    Fujimoto H, Onishi N, Kato N, Takekawa M, Xu XZ, Kosugi A, Kondo T, Imamura M, Oishi I, Yoda A, Minami Y.
    Cell Death Differ; 2006 Jul 31; 13(7):1170-80. PubMed ID: 16311512
    [Abstract] [Full Text] [Related]

  • 18. WIP1 phosphatase at the crossroads of cancer and aging.
    Le Guezennec X, Bulavin DV.
    Trends Biochem Sci; 2010 Feb 31; 35(2):109-14. PubMed ID: 19879149
    [Abstract] [Full Text] [Related]

  • 19. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways.
    Lu X, Nguyen TA, Moon SH, Darlington Y, Sommer M, Donehower LA.
    Cancer Metastasis Rev; 2008 Jun 31; 27(2):123-35. PubMed ID: 18265945
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.